Vical Incorporated (VICL) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 8 PAGES: 33

More Info
									            Vical Incorporated (VICL) - Financial and Strategic Analysis Review

       Reference Code: GDME1730FSA                                                                                        Publication Date: AUG 2010

       10390 Pacific Center Court             Phone             +1 858 6461100                         Revenue            12.7 (million USD)
       San Diego, CA                          Fax               +1 858 6461150                         Net Profit         -28.56 (million USD)
       92121                                  Website           www.vical.com                          Employees          113
       United States                          Exchange          VICL [NASDAQ]                          Industry           Medical Equipment

      Company Overview
       Vical Incorporated (Vical) is a biopharmaceutical company which is principally engaged in the research and development of
       biopharmaceutical products based on its patented DNA delivery technologies. The company also develops certain infectious
       disease vaccines and cancer therapeutics. Vical also provides products which consist of plasmid DNA constructs for non
       commercial applications and cationic lipids. Vical has manufacturing facilities which uses patented purification approaches to
       manufacture naked DNA plasmids in gram quantities. The company also pursues contract manufacturing opportunities to
       leverage its manufacturing facilities which is situated in California.

      Key Executives                                                                   SWOT Analysis
                     Name                                    Title                     Vical Incorporated, SWOT Analysis
       Vijay B. Samant                       Chief Executive Officer                   Strengths                  Weaknesses

       R. Gordon Douglas                     Chairman
                                                                                       Strong Liquidity Position          Low Return on Equity
       Robert C. Merton                      Director
       Robert H. Campbell                    Director                                  Focused Research and               Limited Operating Margin
                                                                                       Development
       Gary A. Lyons                         Director
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData
                                                                                       Opportunities                      Threats
      Share Data
       Vical Incorporated                                                              Growing Aged Population            Healthcare Reform Bill
       Share Price (USD) as on 03-Aug-2010                                      3.40
                                                                            -0.61      Growth in Emerging Markets         Rapid Technological Change
       EPS (USD)
       Market Cap (million USD)                                                 190

       Enterprise Value (million USD)                                           172
                                                                                       Source: Annual Report, Company Website, Primary and Secondary
       Shares Outstanding (million)                                              56    Research
       Source: Annual Report, Company Website, Primary and Secondary Research          GlobalData
       GlobalData

      Financial Performance                                                            Recent Developments
                                                                                       Aug 03, 2010   
								
To top